Compugen Stock Forecast, Price & News

+0.10 (+1.18 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $8.60
50-Day Range
MA: $8.60
52-Week Range
Now: $8.60
Volume875,490 shs
Average Volume1.37 million shs
Market Capitalization$588.41 million
P/E RatioN/A
Dividend YieldN/A
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CGEN
Year FoundedN/A



Sales & Book Value

Annual Sales$17.80 million
Book Value$0.75 per share


Net Income$-27,340,000.00


Market Cap$588.41 million
Next Earnings Date5/5/2021 (Estimated)


Compugen (NASDAQ:CGEN) Stock Price Down 4.8%
April 17, 2021 |
Compugen (NASDAQ:CGEN) PT Lowered to $16.00
April 13, 2021 |
Compugen (NASDAQ:CGEN) Stock Price Up 5%
April 13, 2021 |
Compugen (NASDAQ:CGEN) PT Lowered to $16.00 at SVB Leerink
April 6, 2021 |
Compugen (NASDAQ:CGEN) Stock Price Up 7.2%
April 1, 2021 |
See More Headlines


Overall MarketRank

1.39 out of 5 stars

Medical Sector

676th out of 2,024 stocks

Biological Products, Except Diagnostic Industry

93rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
+0.10 (+1.18 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Compugen (NASDAQ:CGEN) Frequently Asked Questions

Is Compugen a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Compugen stock.
View analyst ratings for Compugen
or view top-rated stocks.

What stocks does MarketBeat like better than Compugen?

Wall Street analysts have given Compugen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Compugen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Compugen?

Compugen saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 6,450,000 shares, an increase of 60.8% from the February 28th total of 4,010,000 shares. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is presently 4.4 days.
View Compugen's Short Interest

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Compugen

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings data on Thursday, February, 25th. The biotechnology company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). The biotechnology company earned $2 million during the quarter. The business's revenue for the quarter was up 19900.0% compared to the same quarter last year. During the same period last year, the company posted ($0.10) EPS.
View Compugen's earnings history

How has Compugen's stock been impacted by COVID-19?

Compugen's stock was trading at $11.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CGEN shares have decreased by 27.3% and is now trading at $8.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CGEN?

6 brokerages have issued 12-month price objectives for Compugen's shares. Their forecasts range from $16.00 to $22.00. On average, they anticipate Compugen's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 120.9% from the stock's current price.
View analysts' price targets for Compugen
or view top-rated stocks among Wall Street analysts.

Who are Compugen's key executives?

Compugen's management team includes the following people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 54, Pay $989.87k)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 48, Pay $545.18k)
  • Dr. Oliver Froescheis Ph.D., Sr. VP of Corp. & Bus. Devel. (Age 55, Pay $453.25k)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 53, Pay $339.19k)
  • Dr. Henry Adewoye M.D., Sr. VP & Chief Medical Officer (Age 56, Pay $589.09k)
  • Ms. Donna Gershowitz, Gen. Counsel (Age 57)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 52)
  • Ms. Dorit Amitay, VP of HR (Age 53)
  • Dr. Yaron Turpaz M.B.A., Ph.D., MBA, Sr. VP & Sr. Advisor of Computational Discovery (Age 50)
  • Rivka Schwartz, VP Research and Discovery

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen CEO Anat Cohen-Dayag on Anat Cohen-Dayag has an approval rating of 100% among Compugen's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Compugen's key competitors?

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Rothschild Investment Corp IL (0.58%), Defender Capital LLC. (0.34%), HighPoint Advisor Group LLC (0.03%), Crestwood Advisors Group LLC (0.03%) and Phoenix Wealth Advisors (0.02%).

Which institutional investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Phoenix Wealth Advisors.

Which institutional investors are buying Compugen stock?

CGEN stock was acquired by a variety of institutional investors in the last quarter, including Defender Capital LLC., Rothschild Investment Corp IL, HighPoint Advisor Group LLC, and Crestwood Advisors Group LLC.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $8.60.

How much money does Compugen make?

Compugen has a market capitalization of $588.41 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does Compugen have?

Compugen employs 68 workers across the globe.

What is Compugen's official website?

The official website for Compugen is

Where are Compugen's headquarters?

Compugen is headquartered at Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]

This page was last updated on 4/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.